Nutriband (NASDAQ:NTRB) Stock Price Up 3.6% – Still a Buy?

Posted by Hanz Christensen on Aug 14th, 2026

Nutriband Inc. (NASDAQ:NTRB – Get Free Report) shares traded up 3.6% during trading on Thursday . The company traded as high as $3.26 and last traded at $3.19. Approximately 2,350 shares were traded during mid-day trading, a decline of 72% from the average session volume of 8,313 shares. The stock had previously closed at $3.08.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nutriband has a consensus rating of “Reduce”.

Read Our Latest Analysis on NTRB

Nutriband Stock Up 3.6%

The stock’s 50 day moving average price is $3.10 and its 200-day moving average price is $3.67. The stock has a market capitalization of $38.79 million, a PE ratio of -1.24 and a beta of 1.98.

Nutriband (NASDAQ:NTRB – Get Free Report) last issued its quarterly earnings results on Thursday, June 11th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $0.43 million for the quarter. Nutriband had a negative return on equity of 112.64% and a negative net margin of 448.25%.

Institutional Trading of Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Cogent Private Wealth Inc. acquired a new stake in Nutriband Inc. (NASDAQ:NTRB – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned about 0.13% of Nutriband at the end of the most recent quarter. 19.70% of the stock is currently owned by institutional investors and hedge funds.

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.